AFTPF (AFT Pharmaceuticals) Debt-to-EBITDA : 0.70 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is AFT Pharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

AFT Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.48 Mil. AFT Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $19.10 Mil. AFT Pharmaceuticals's annualized EBITDA for the quarter that ended in Mar. 2024 was $28.09 Mil. AFT Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.70.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for AFT Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

AFTPF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.17 Med: 1.83 Max: 6.45
Current: 1.16

During the past 9 years, the highest Debt-to-EBITDA Ratio of AFT Pharmaceuticals was 6.45. The lowest was -3.17. And the median was 1.83.

AFTPF's Debt-to-EBITDA is ranked better than
58.63% of 655 companies
in the Drug Manufacturers industry
Industry Median: 1.8 vs AFTPF: 1.16

AFT Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for AFT Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AFT Pharmaceuticals Debt-to-EBITDA Chart

AFT Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-EBITDA

Get a 7-Day Free Trial

2.17

3.40

1.83

1.87

1.16

AFT Pharmaceuticals Semi-Annual Data
	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial												1.27	-	1.17	3.96	0.70

Competitive Comparison of AFT Pharmaceuticals's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AFT Pharmaceuticals's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's Debt-to-EBITDA falls into.

AFT Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

AFT Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.484	+	19.096)	/	16.86
	=	1.16

AFT Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.484	+	19.096)	/	28.088
	=	0.70

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Mar. 2024) EBITDA data.

AFT Pharmaceuticals (OTCPK:AFTPF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

AFT Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AFT Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

AFT Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (OTCPK:AFTPF) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

AFT:New Zealand AFP:Australia

Address

129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622

Website

https://www.aftpharm.com

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.